J1 9lr3098 CF HB 33

By: Senator Zirkin

Introduced and read first time: February 14, 2019

Assigned to: Rules

Re-referred to: Judicial Proceedings, February 22, 2019

Committee Report: Favorable with amendments

Senate action: Adopted

Read second time: March 13, 2019

CHAPTER _____

- 1 AN ACT concerning
- 2 Medical Cannabis Provider Applications Opioid Use Disorder
- 3 FOR the purpose of encouraging the Natalie M. LaPrade Medical Cannabis Commission to
- 4 approve provider applications for patients who have an opioid use disorder only
- 5 under certain circumstances; and generally relating to provider applications for
- 6 medical cannabis for patients with an opioid use disorder.
- 7 BY repealing and reenacting, with amendments,
- 8 Article Health General
- 9 Section 13–3304(d)
- 10 Annotated Code of Maryland
- 11 (2015 Replacement Volume and 2018 Supplement)
- 12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
- 13 That the Laws of Maryland read as follows:
- 14 Article Health General
- 15 13–3304.
- 16 (d) (1) The Commission is encouraged to approve provider applications for the
- 17 following medical conditions:

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

<u>Underlining</u> indicates amendments to bill.

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.



1 2	(i) A chronic or debilitating disease or medical condition that results in a patient being admitted into hospice or receiving palliative care; [or]
3	(II) AN OPIOID USE DISORDER ONLY IF:
4 5	1. The patient tried all other traditional treatments for opioid use disorder and was unsuccessful; or
6 7	2. The patient will use the medical cannabis in conjunction with traditional therapies; or
8 9	[(ii)] (III) A chronic or debilitating disease or medical condition or the treatment of a chronic or debilitating disease or medical condition that produces:
10	1. Cachexia, anorexia, or wasting syndrome;
11	2. Severe or chronic pain;
12	3. Severe nausea;
13	4. Seizures; or
14	5. Severe or persistent muscle spasms.
15 16	(2) The Commission may not limit treatment of a particular medical condition to one class of providers.
17 18	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect October 1, 2019.
	Approved:
	Governor.
	President of the Senate.
	Speaker of the House of Delegates